Market ExpansionModerna's mRESVIA received an FDA label expansion approval to treat adults 18-59 at high-risk of severe disease, broadening the addressable market.
Regulatory FilingsRegulatory filings for the flu and flu+COVID combination vaccine (mRNA-1083) will be submitted shortly, highlighting a significant commercial opportunity.
Vaccine EfficacyMRNA-1010 achieved superior vaccine efficacy to Fluarix in Phase III study, opening up regulatory path for a combination flu/COVID vaccine.